ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S ...

Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the U.S. Court of Appeals has upheld the validity of its patent for ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 26.1% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals ACAD, expressing a variety ...

US Court of Appeals upholds Acadia Pharmaceuticals' patent for Nuplazid, securing protection against generic competition ...

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) rallied 26% after the company secured another court win that further solidified Nuplazid’s intellectual property position. The stock is now back to ...

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...